All News

In an interview with CURE, Anees B. Chagpar, from The Breast Center at Smilow Cancer Hospital at Yale-New Haven, shares her thoughts on the final guidelines and how they change the focus of screening.

Doing a little reflection about where I've been and how far I've come is just as important as making resolutions.

I am not fearless. But, despite all that this disease has taken from me, I will fight to take something back.

The approval was based on findings from the phase 3 ENDEAVOR trial.

For some patients, doctors recommend treatment after surgery to reduce the risk of melanoma developing again.

Why does a cancer diagnosis always come down to being a winner or a loser?

The cancer experience is different for all of us that is sometimes easy to navigate and sometimes not at all. Yet we all join the same team once we hear the words “you have cancer.” We can help each other to cope.

The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.

The first thing cancer took away was my innocence. I still remember what it was like to hear those five words: "I'm sorry, you have cancer."

Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.

Though patients and survivors often complain of chemo brain during and after treatment for cancer, a growing body of research shows that there are multiple causes behind the cognitive decline many survivors experience.

Studies continue to show increased risk of cancer recurrence and death in obese individuals, but new research highlights the benefits of weight loss interventions for overweight and obese cancer survivors.

A five-year breast cancer survivor expresses uncertainty about discontinuing her hormone-suppressing medication.

A poem about a two-year encounter with advanced cancer of the head and neck.

CURE sat down with Smita Bhatia to discuss her lecture and key issues in cancer survivorship.

In her talk at the 2016 Cancer Survivorship Symposium, Deborah Korenstein suggested a way forward, grounded in a more individualized approach to survivorship care.

Interim results from the study of 26 individuals were presented by Danielle Novetsky Friedman at the 2016 Cancer Survivorship Symposium held in San Francisco.

Amid all the excitement over recently approved immunotherapies and targeted drugs for the treatment of later-stage melanoma is an important emerging message: In many cases, two is better than one.

McCabe addressed this topic and others in her talk, "Models of Delivery" at the 2016 Cancer Survivorship Symposium in San Francisco.

Survivors of testicular cancer may face an increased vulnerability to additional health problems after being treated with cisplatin-based chemotherapy.

Melanoma has been a primary focus in immunotherapy research because of intriguing evidence that some people's immune systems are better able to keep the cancer in check.